Positive News Sentiment NASDAQ:KTRA Kintara Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kintara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.24 -0.01 (-4.02%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$0.23▼$0.2550-Day Range$0.15▼$0.3152-Week Range$0.14▼$2.02Volume1.26 million shsAverage Volume4.75 million shsMarket Capitalization$15.64 millionP/E RatioN/ADividend YieldN/APrice Target$3.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Kintara Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside1,436.1% Upside$3.67 Price TargetShort InterestHealthy0.65% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.51) to $0.03 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.68 out of 5 starsMedical Sector844th out of 1,433 stocksPharmaceutical Preparations Industry425th out of 683 stocks 3.4 Analyst's Opinion Consensus RatingKintara Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.67, Kintara Therapeutics has a forecasted upside of 1,436.1% from its current price of $0.24.Amount of Analyst CoverageKintara Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.65% of the outstanding shares of Kintara Therapeutics have been sold short.Short Interest Ratio / Days to CoverKintara Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kintara Therapeutics has recently decreased by 35.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKintara Therapeutics does not currently pay a dividend.Dividend GrowthKintara Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KTRA. Previous Next 2.7 News and Social Media Coverage News SentimentKintara Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.Search InterestOnly 4 people have searched for KTRA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Kintara Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kintara Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.90% of the stock of Kintara Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 10.37% of the stock of Kintara Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kintara Therapeutics are expected to grow in the coming year, from ($0.51) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kintara Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kintara Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kintara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Kintara Therapeutics (NASDAQ:KTRA) StockKintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.Read More KTRA Stock News HeadlinesJune 21, 2022 | finance.yahoo.comKintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare ConferenceJune 17, 2022 | americanbankingnews.comKintara Therapeutics, Inc. (NASDAQ:KTRA) Short Interest UpdateJune 15, 2022 | msn.comKintara Therapeutics' Stock Shooting Higher As FDA Grants Fast Track Designation To Brain Cancer DrugJune 15, 2022 | benzinga.comWhy Kintara Therapeutics Shares Are Skyrocketing TodayJune 15, 2022 | seekingalpha.comKintara Therapeutics gains after FDA fast track nod for brain cancer treatment VAL-083June 15, 2022 | finance.yahoo.comKintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed GlioblastomaJune 10, 2022 | finance.yahoo.comKintara Therapeutics to Present at the JMP Securities Life Sciences ConferenceJune 3, 2022 | baystreet.caKintara in DangerJune 3, 2022 | finance.yahoo.comKintara Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price RequirementMay 31, 2022 | ca.proactiveinvestors.comKazia Therapeutics’ paxalisib now the subject of multi-drug platform study at the University Hospital, ZurichMay 25, 2022 | finance.yahoo.com7 Penny Stocks With 10x Potential This YearMay 13, 2022 | finance.yahoo.comKintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results and Provides Corporate UpdateMay 4, 2022 | proactiveinvestors.com.auKazia Therapeutics and its flagship asset have made significant progress against brain cancers: Pitt Street ResearchApril 26, 2022 | finance.yahoo.comKintara Therapeutics to Present at the Planet MicroCap Showcase 2022April 14, 2022 | finance.yahoo.comKintara Announces Closing of $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesApril 12, 2022 | seekingalpha.comKintara Therapeutics stock slumps on $8.6M securities offeringApril 12, 2022 | finance.yahoo.comKintara Announces $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesApril 11, 2022 | finance.yahoo.comKintara Therapeutics Presents Data at the 2022 American Association for Cancer Research Annual MeetingMarch 22, 2022 | finance.yahoo.comKintara Therapeutics to Present at the Maxim Group 2022 Virtual Growth ConferenceMarch 15, 2022 | finance.yahoo.comKintara Therapeutics Announces Data Presentation at the 2022 American Association for Cancer Research Annual MeetingFebruary 14, 2022 | finance.yahoo.comKTRA: A Farewell to GBMFebruary 11, 2022 | seekingalpha.comKintara Therapeutics GAAP EPS of -$0.12 beats by $0.05February 11, 2022 | finance.yahoo.comKintara Therapeutics Announces Fiscal 2022 Second Quarter Financial Results and Provides Corporate UpdateFebruary 4, 2022 | benzinga.comKintara Therapeutics Announces Issuance Of New US Patent Related To VAL-083 And MGMT ResistanceFebruary 4, 2022 | finance.yahoo.comKintara Therapeutics to Present at BIO CEO & Investor Conference on February 15, 2022See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KTRA CUSIPN/A CIK1498382 Webwww.kintara.com Phone(858) 350-4364Fax604-608-5685Employees4Year FoundedN/ACompany Calendar Last Earnings5/13/2022Today7/07/2022Next Earnings (Estimated)10/05/2022Fiscal Year End6/30/2023Price Target and Rating Average Stock Price Forecast$3.67 High Stock Price Forecast$5.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+1,436.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,300,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-144.27% Debt Debt-to-Equity RatioN/A Current Ratio3.12 Quick Ratio3.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.13) per share Price / Book-1.84Miscellaneous Outstanding Shares65,530,000Free Float61,667,000Market Cap$15.64 million OptionableNot Optionable Beta1.23 Kintara Therapeutics Frequently Asked Questions Should I buy or sell Kintara Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kintara Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Kintara Therapeutics stock. View analyst ratings for Kintara Therapeutics or view top-rated stocks. What is Kintara Therapeutics' stock price forecast for 2022? 4 Wall Street research analysts have issued 12-month price objectives for Kintara Therapeutics' stock. Their KTRA stock forecasts range from $3.00 to $5.00. On average, they predict Kintara Therapeutics' share price to reach $3.67 in the next twelve months. This suggests a possible upside of 1,436.1% from the stock's current price. View analysts' price targets for Kintara Therapeutics or view top-rated stocks among Wall Street analysts. How has Kintara Therapeutics' stock price performed in 2022? Kintara Therapeutics' stock was trading at $0.51 at the start of the year. Since then, KTRA shares have decreased by 53.2% and is now trading at $0.2387. View the best growth stocks for 2022 here. When is Kintara Therapeutics' next earnings date? Kintara Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, October 5th 2022. View our earnings forecast for Kintara Therapeutics. How were Kintara Therapeutics' earnings last quarter? Kintara Therapeutics, Inc. (NASDAQ:KTRA) announced its quarterly earnings data on Friday, May, 13th. The company reported ($0.11) EPS for the quarter, hitting analysts' consensus estimates of ($0.11). View Kintara Therapeutics' earnings history. When did Kintara Therapeutics' stock split? How did Kintara Therapeutics' stock split work? Shares of Kintara Therapeutics reverse split on the morning of Wednesday, May 8th 2019. The 1-10 reverse split was announced on Tuesday, May 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 7th 2019. An investor that had 100 shares of Kintara Therapeutics stock prior to the reverse split would have 10 shares after the split. Who are Kintara Therapeutics' key executives? Kintara Therapeutics' management team includes the following people: Mr. Robert E. Hoffman C.P.A., CPA, Pres, CEO & Chairman (Age 56, Pay $95k)Mr. Scott Praill B.Sc., C.P.A., CA, CPA, BSc, CFO & Sec. (Age 55, Pay $369.81k)Mr. Jeffrey A. Bacha B.Sc., M.B.A., Founder (Age 54)Dr. Dennis M. Brown B.Sc., M.A., Ph.D., Co-Founder & Chief Scientific Officer (Age 72)Mr. Greg A. Johnson, Acting Head of Operations Who are some of Kintara Therapeutics' key competitors? Some companies that are related to Kintara Therapeutics include Opiant Pharmaceuticals (OPNT), Medicenna Therapeutics (MDNA), Oncotelic Therapeutics (OTLC), Athersys (ATHX), Lumos Pharma (LUMO), Palatin Technologies (PTN), Palatin Technologies (PTN), InflaRx (IFRX), BioLineRx (BLRX), vTv Therapeutics (VTVT), 89bio (ETNB), Lantern Pharma (LTRN), PLx Pharma (PLXP), Trevena (TRVN) and BeyondSpring (BYSI). View all of KTRA's competitors. What other stocks do shareholders of Kintara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kintara Therapeutics investors own include Ampio Pharmaceuticals (AMPE), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), (DMPI), Fortress Biotech (FBIO), Immunic (IMUX), Miragen Therapeutics (MGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN). What is Kintara Therapeutics' stock symbol? Kintara Therapeutics trades on the NASDAQ under the ticker symbol "KTRA." How do I buy shares of Kintara Therapeutics? Shares of KTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kintara Therapeutics' stock price today? One share of KTRA stock can currently be purchased for approximately $0.24. How much money does Kintara Therapeutics make? Kintara Therapeutics (NASDAQ:KTRA) has a market capitalization of $15.64 million. The company earns $-38,300,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. How many employees does Kintara Therapeutics have? Kintara Therapeutics employs 4 workers across the globe. How can I contact Kintara Therapeutics? Kintara Therapeutics' mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The official website for Kintara Therapeutics is www.kintara.com. The company can be reached via phone at (858) 350-4364, via email at ir@delmarpharma.com, or via fax at 604-608-5685. This page (NASDAQ:KTRA) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
